Gastrointestinal stromal tumor

Dr. Breelyn Wilky discusses some of the most recent advancements in GIST treatment, as well as touched on the role of personalized therapy.

Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, including GIST and some leukemias.

A new endoscopic tunneling method, STER, allowed a patient to have a GIST removed without surgery, allowing quicker recovery and fewer complications.

A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following progression on Gleevec.

SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver metastases resistant to TKI therapy.

Alternating between Glivec and Stivarga therapy didn't impact survival outcomes; it led to more toxicity and discontinuations in patients with GIST.

HT-KIT, a novel targeted therapy for GIST, demonstrated the ability to reduce tumor burden in humanized mouse models and induce tumor cell death.

RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according to study findings.

Treatment with pimitespib was associated with stable disease in two-thirds of patients with advanced gastrointestinal stromal tumors.

Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing mutation testing for treatment decisions.

The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.

Patients with non-metastatic GIST treated with neoadjuvant TKIs prior to surgery experienced a benefit which led to less invasive or complex surgeries.

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.

Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others in patients with GIST.

Both laparoscopic wedge and endoscopic resection are safe and feasible treatment approaches for patients with gastric gastrointestinal stromal tumors.

Researchers are advising against the interruption of treatment with Gleevec among patients with advanced gastrointestinal stromal tumors.

From YouTuber Grace Helbig announcing her cancer diagnosis to the NFL’s Foster Moreau being in full remission, here’s what’s happening in the oncology space this week.

Patients with GIST have more treatment options than ever, with others currently under development.

The National Comprehensive Cancer Network updated their guidelines to state that Qinlock is the recommended second-line treatment for patients with Sutent-intolerant gastrointestinal stromal tumors.

As a doctor, I’m used to providing medical care, but once I was diagnosed with cancer, I became a patient — someone receiving medical care, too.

Nearly two thirds of patients with GISTs — a rare type of cancer that often begins in the digestive system — indicated that their overall quality of life after treatment had been affected by cancer-related cognitive impairments, also referred to as “chemo brain,” according to analysis of survey data.

The location of gastrointestinal stromal tumors in the stomach predicts the mutation profile and drug sensitivity, which can provide direction for treatment decisions and selective genomic testing.

Gastrointestinal stromal tumors that are SDH deficient are less likely to respond to TKI treatment. A researcher discusses the exploration of a new drug that can work in this patient population.

Patients, clinicians and researchers should work together to find new therapies for rare cancers, one expert says.

Will patients be given a placebo? Are clinical trials safe? An expert answers these questions and more.

The combination of Gleevec and Xpovio demonstrated some promising results in a small group of patients with a rare form of advanced gastrointestinal cancer whose disease had failed to respond to prior first-line treatment with Gleevec.

The findings open up the door for a fourth-line treatment option in patients with advanced gastrointestinal stromal tumors with disease progression.

Treatment with the study drug was associated with a doubling of a survival outcome in patients with advanced gastrointestinal stromal tumor, compared to placebo.

Twice-daily treatment with Qinlock following disease progression after treatment with fourth-line therapy in patients with advanced gastrointestinal stromal tumor was associated with extended survival outcomes.